<?xml version='1.0' encoding='utf-8'?>
<document id="26861654"><sentence text="Relationship Between Buprenorphine Dosing and Triglyceride Lowering and creatine kinase [corrected]  Elevation in Felines: Possible Human Implications."><entity charOffset="21-34" id="DDI-PubMed.26861654.s1.e0" text="Buprenorphine" /><entity charOffset="46-58" id="DDI-PubMed.26861654.s1.e1" text="Triglyceride" /><pair ddi="false" e1="DDI-PubMed.26861654.s1.e0" e2="DDI-PubMed.26861654.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26861654.s1.e0" e2="DDI-PubMed.26861654.s1.e1" /></sentence><sentence text="Recently published feline data suggest that high doses of buprenorphine can elevate creatine kinase (CK)  [corrected] and profoundly influence triglyceride levels in an inverted dose versus effect relationship"><entity charOffset="58-71" id="DDI-PubMed.26861654.s2.e0" text="buprenorphine" /><entity charOffset="84-92" id="DDI-PubMed.26861654.s2.e1" text="creatine" /><entity charOffset="143-155" id="DDI-PubMed.26861654.s2.e2" text="triglyceride" /><pair ddi="false" e1="DDI-PubMed.26861654.s2.e0" e2="DDI-PubMed.26861654.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26861654.s2.e0" e2="DDI-PubMed.26861654.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26861654.s2.e0" e2="DDI-PubMed.26861654.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26861654.s2.e1" e2="DDI-PubMed.26861654.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26861654.s2.e1" e2="DDI-PubMed.26861654.s2.e2" /></sentence><sentence text=" This intriguing observation in felines, hitherto not documented for buprenorphine, should be considered in human situations for any trends of translatability"><entity charOffset="69-82" id="DDI-PubMed.26861654.s3.e0" text="buprenorphine" /></sentence><sentence text=" The report evaluates the observed effects in domestic cats and what is known about buprenorphine in human subjects"><entity charOffset="84-97" id="DDI-PubMed.26861654.s4.e0" text="buprenorphine" /></sentence><sentence text=" Based on the objective assessment, the following are deduced: (a) although elevated CK levels is a nonissue in humans, one needs to pay attention especially when buprenorphine is used at the high end of therapeutic dose range in the presence of drugs that can impair the hepatic metabolism of buprenorphine; and (b) the potential for triglyceride lowering can be easily confirmed in human trials, and since it may occur at the relevant therapeutic doses of buprenorphine, it may be beneficial in such patients who may have added cardiovascular risk factors"><entity charOffset="163-176" id="DDI-PubMed.26861654.s5.e0" text="buprenorphine" /><entity charOffset="294-307" id="DDI-PubMed.26861654.s5.e1" text="buprenorphine" /><entity charOffset="335-347" id="DDI-PubMed.26861654.s5.e2" text="triglyceride" /><entity charOffset="458-471" id="DDI-PubMed.26861654.s5.e3" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.26861654.s5.e0" e2="DDI-PubMed.26861654.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26861654.s5.e0" e2="DDI-PubMed.26861654.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26861654.s5.e0" e2="DDI-PubMed.26861654.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26861654.s5.e0" e2="DDI-PubMed.26861654.s5.e3" /><pair ddi="false" e1="DDI-PubMed.26861654.s5.e1" e2="DDI-PubMed.26861654.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26861654.s5.e1" e2="DDI-PubMed.26861654.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26861654.s5.e1" e2="DDI-PubMed.26861654.s5.e3" /><pair ddi="false" e1="DDI-PubMed.26861654.s5.e2" e2="DDI-PubMed.26861654.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26861654.s5.e2" e2="DDI-PubMed.26861654.s5.e3" /></sentence><sentence text="" /></document>